Related Experiment Video
Updated: Jun 3, 2026
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
[Therapeutic impact of alpha interferon in chronic myelogenous leukaemia]
A Tolo-Diebkilé1, K G Koffi, G D Sawadogo
1CHU de Yopougon. tolo_aissata@yahoo.fr
Context:
Ten years after the use of alpha interferon in chronic myelogenous (CML) leukaemia treatment, we review this treatment.
Objective:
We propose through this study to evaluate the therapeutic answer of the patients reached of CML in chronic phase and to study its impact on survival.
Material And Methods:
To be done we carried out a descriptive and analytical retrospective study concerning 40 patients carrying Chronic Myelogenous Leukaemia.
Results:
The average age was 39.05 years and ratio sex was 0.9. 60% of the patients profited from the arm Hydroxyurea + Interferon alpha + Cytosine Arabinoside and 40% from Hydroxyurea + Interferon. The complete haematological answer was observed in 85.5%. The cytogenetic answer was documented only for two cases, and it acted of complete answer. On the evolutionary level, it was noted 27.5% of deaths related to a blastic transformation. The side effects were marked by occurred of alopecia, herpes and the gripal syndrome. The median of survival observed was 68.233 months or 5.68 years. The age, socioeconomic level, delay of treatment started, therapeutic protocol, length and regularity of treatment influenced the therapeutic response.
Conclusion:
Many factors influence the treatment response.
